Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

Ramón Garcia-Sanz*, Marzia Varettoni, Cristina Jiménez, Simone Ferrero, Stephanie Poulain, Jesus F. San-Miguel, Maria L. Guerrera, Daniela Drandi, Tina Bagratuni, Mary McMaster, Aldo M. Roccaro, Damien Roos-Weil, Merav Leiba, Yong Li, Luigi Qiu, Jian Hou, C. Fernandez De Larrea, Jorge J. Castillo, M. Dimopoulos, R. G. OwenS. P. Treon, Z. R. Hunter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Apart from the MYD88L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring. Key recommendations from IWWM-11 CP3 included: (1) molecular studies are warranted for patients in whom therapy is going to be started; such studies should also be done in those whose bone marrow (BM) material is sampled based on clinical issues; (2) molecular studies considered essential for these situations are those that clarify the status of 6q and 17p chromosomes, and MYD88, CXCR4, and TP53 genes. These tests in other situations, and/or other tests, are considered optional; (3) independently of the use of more sensitive and/or specific techniques, the minimum requirements are allele specific polymerase chain reaction for MYD88L265P and CXCR4S338X using whole BM, and fluorescence in situ hybridization for 6q and 17p and sequencing for CXCR4 and TP53 using CD19+ enriched BM; (4) these requirements refer to all patients; therefore, sample should be sent to specialized centers.

Original languageEnglish
Pages (from-to)90-96
Number of pages7
JournalSeminars in Hematology
Volume60
Issue number2
DOIs
StatePublished - Mar 2023
Externally publishedYes

Funding

FundersFunder number
Abbvie/Pharmacyclics
Beigene Pharmaceuticals
Cellectar Biosciences, Inc.
International Waldenstrom's Macroglobulinemia Foundation
Janssen Pharmaceuticals

    Keywords

    • CXCR4
    • IgM MGUS
    • MYD88
    • TERT
    • TP53
    • Waldenström's Macroglobulinemia

    Fingerprint

    Dive into the research topics of 'Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia'. Together they form a unique fingerprint.

    Cite this